Live Breaking News & Updates on Pascalyne Wilson

Stay updated with breaking news from Pascalyne wilson. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Cellectis S A : Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications

Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications

12 Jun 2024 22:30 CEST

. ....

France General , North Carolina , United States , New York , Ashleyr Robinson , Pascalyne Wilson , Cellecti Pulseagile , Patricia Sosa Navarro , Arthur Stril , Julien Valton , Cellectis The Company Euronext Growth , Securities Exchange Commission , Nature Communications , Euronext Growth , Vice President Gene Therapy , Adult Hemoglobin , Sickle Hemoglobin , Nasdaq Global Market , Private Securities Litigation Reform Act , Annual Report , Sosa Navarro , Interim Chief Financial Officer , Lifesci Advisors ,

Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications

Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

France General , New York , United States , North Carolina , Pascalyne Wilson , Cellecti Pulseagile , Julien Valton , Patricia Sosa Navarro , Arthur Stril , Ashleyr Robinson , Securities Exchange Commission , Nature Communications , Cellectis The Company Euronext Growth , Non Viral Gene Therapy Approach , Sickle Cell Disease , Euronext Growth , Vice President Gene Therapy , Adult Hemoglobin , Sickle Hemoglobin , Nasdaq Global Market , Private Securities Litigation Reform Act , Annual Report , Sosa Navarro , Interim Chief Financial Officer , Lifesci Advisors ,

Cellectis Unveils a Non-Viral Gene Therapy Approach for Sickle Cell Disease in Nature Communications

NEW YORK, June 12, 2024 (GLOBE NEWSWIRE) Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell ....

France General , New York , United States , North Carolina , Julien Valton , Pascalyne Wilson , Arthur Stril , Cellecti Pulseagile , Ashleyr Robinson , Patricia Sosa Navarro , Cellectis The Company Euronext Growth , Securities Exchange Commission , Nature Communications , Euronext Growth , Vice President Gene Therapy , Adult Hemoglobin , Sickle Hemoglobin , Nasdaq Global Market , Private Securities Litigation Reform Act , Annual Report , Sosa Navarro , Interim Chief Financial Officer , Lifesci Advisors ,

Monthly information on share capital and company voting

(Article 223-16 of General Regulation of the French financial markets authority) PARIS, June 05, 2024 (GLOBE NEWSWIRE) Listing market: Euronext. ....

France General , Patricia Sosa Navarro , Arthur Stril , Ashleyr Robinson , Pascalyne Wilson , General Regulation , Sosa Navarro , Interim Chief Financial Officer , Lifesci Advisors ,

Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic Leukemia

Cellectis Receives Orphan Drug Designation for UCART22, its Allogeneic CAR T Product for Patients with Acute Lymphoblastic Leukemia
tmcnet.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tmcnet.com Daily Mail and Mail on Sunday newspapers.

United States , North Carolina , New York , France General , Ashleyr Robinson , Arthur Stril , Mark Frattini , Pascalyne Wilson , Patricia Sosa Navarro , American Society Of Hematology , Cellectis The Company Euronext Growth , European Medicines Agency , European Union , Securities Exchange Commission , Committee For Orphan Medicinal Products , European Commission , Receives Orphan Drug Designation , Acute Lymphoblastic , Euronext Growth , Orphan Drug Designation , Acute Lymphoblastic Leukemia , Chief Medical Officer , American Society , Dose Level , Orphan Medicinal , Nasdaq Global Market ,